Clinical Features of Fixed Drug Eruption at a Tertiary Hospital in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Jae-Woo | - |
dc.contributor.author | Cho, Sang-Heon | - |
dc.contributor.author | Kim, Kyu-Han | - |
dc.contributor.author | Min, Kyung-Up | - |
dc.contributor.author | Kang, Hye-Ryun | - |
dc.date.available | 2019-03-08T21:02:12Z | - |
dc.date.issued | 2014-09 | - |
dc.identifier.issn | 2092-7355 | - |
dc.identifier.issn | 2092-7363 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/11869 | - |
dc.description.abstract | Purpose: Fixed drug eruption (FDE) is characterized by a well-defined erythematous patch, plaque, or bullous eruption that recurs at the same site as the result of systemic exposure to a causative drug, and resolves with or without hyperpigmentation. This study was carried out to identify the common causative drugs and clinical features of FDE in Korea. Methods: We reviewed electronic medical records of all patients diagnosed with FDE from January 2000 to December 2010 at a tertiary hospital in Korea. Results: A total of 134 cases were diagnosed as FDE. The mean age was 35.9 years (range, 0-82 years) and 69 (51.5%) of the patients were male. The mean duration from the first event to attending hospital was 1.9 years (range, 1-20 years). The mean number of recurrences was 2.6 (1-10), and 72.6% of patients sought medical care after experiencing symptoms twice or more. Four patients (3.1%) needed hospitalization. The most common sites were the upper extremities (47.7%), followed by the lower extremities, face, abdomen, chest, buttocks and perineum. Clear documentation on the causative drugs was available for 38 patients (28.4%), and among these, non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen accounted for 71.1% of cases, and antibiotics accounted for 15.8%. Eighty patients (59.7%) underwent active treatment for FDE, and topical steroids were most frequently prescribed (43.3%), with systemic steroids used in 11.2% of patients. Conclusions: NSAIDs and acetaminophen were the main causative agents of FDE, however, the causative agents were not assessed in 25% of patients. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY | - |
dc.title | Clinical Features of Fixed Drug Eruption at a Tertiary Hospital in Korea | - |
dc.type | Article | - |
dc.identifier.doi | 10.4168/aair.2014.6.5.415 | - |
dc.identifier.bibliographicCitation | ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, v.6, no.5, pp 415 - 420 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000341741200006 | - |
dc.identifier.scopusid | 2-s2.0-84906956096 | - |
dc.citation.endPage | 420 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 415 | - |
dc.citation.title | ALLERGY ASTHMA & IMMUNOLOGY RESEARCH | - |
dc.citation.volume | 6 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Fixed drug eruption | - |
dc.subject.keywordAuthor | non-steroidal anti-inflammatory drug | - |
dc.subject.keywordPlus | LYMPHOCYTE-TRANSFORMATION TEST | - |
dc.subject.keywordPlus | CUTANEOUS REACTIONS | - |
dc.subject.keywordPlus | TESTS | - |
dc.subject.keywordPlus | HYPERSENSITIVITY | - |
dc.subject.keywordPlus | PATTERN | - |
dc.relation.journalResearchArea | Allergy | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Allergy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.